Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Y-6 Sublingual Tablets in Acute Ischemic Stroke Patients Undergoing Reperfusion Therapy
CTR20231130Phase 2Completed
- Sponsor
- Nanjing NeuroDawn Pharmaceutical
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cilostazol + dexborneol in ischemic stroke, sponsored by Nanjing NeuroDawn Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
cilostazol + dexborneol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20231130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231130.